Aims: an association between T2DM and cognitive impairment has been reported among Western populations, but data are limited in other settings. We investigated the cross-sectional association between fasting blood glucose (FBG) and cognition in an older Chinese population. Methods: the Guangzhou Biobank Cohort Study included 27,971 individuals (50-96 years, mean age 61.5 years, 72% female) with measures of cognitive function assessed using modified Delayed Word Recall Test (DWRT) and Mini-Mental State Examination (MMSE). Fasting glucose and lipids, and potential confounders were measured. Results: after adjustment for potential confounders, the risk for cognitive impairment as measured by DWRT, significantly increased [odds ratio (OR) = 1.18, 95% CI 1.00-1.40] but the association was of borderline significance when measured by MMSE (OR = 1.04, 95% CI 0.73-1.47) in those with diabetes relative to those without diabetes. Fasting blood glucose was significantly negatively associated with cognitive function as measured by DWRT but not MMSE, with an increase of 1 mmol/l of FBG associated with a decrease of 0.02 in DWRT (P < 0.05, 95% CI −0.03 to −0.002) and 0.03 in MMSE score (P = 0.114, 95% CI −0.06-0.01).
Introduction
Older adults are at increased risk of developing both type 2 diabetes mellitus (T2DM) and cognitive impairment with evidence from Western populations increasingly suggesting a strong link between the two conditions [1] . Individuals with T2DM are more likely to have lower Mini-Mental State Examination (MMSE) scores compared with those without the condition [2] . Data have generally described Caucasian populations, including the Framingham Study [3] which demonstrated an association between T2DM and cognitive impairment, although a Hong Kong Chinese sample showed that those receiving treatment for T2DM were more likely to have cognitive impairment than those not receiving treatment [4] . Indeed, the association has been studied in a Japanese sample, demonstrating diabetes as a risk factor for the development of dementia; however, the association with sub-clinical cognitive impairment was not assessed [5] . Furthermore, several studies have not observed an association between T2DM and cognitive impairment [6] .
The extent to which glycaemia in people with or without diabetes affects cognition remains to be established, particularly in non-Caucasian populations [7] . To test the hypothesis of an association between glycaemia and cognitive impairment in an older Chinese population, baseline data from the Guangzhou Biobank Cohort Study (GBCS) were analysed.
Patients and methods
The GBCS baseline data were collected during September 2003 to January 2008; the sample for the present study included 27,971 individuals. Participants were randomly recruited to the GBCS from an unofficial organisation affiliated with the local government: the 'Guangzhou Health and Happiness Association for the Respectable Elders' (GHHARE) open to all aged ≥50 years. Further information describing the GBCS has been previously reported [8] . Participants were aged ≥50 years, ambulatory, capable of consenting and not receiving treatment of life-threatening conditions. All participants gave informed consent before data were collected using a computer-based questionnaire by face-to-face interviews conducted by trained nurses at the Guangzhou Number 12 Hospital. The study was approved by the Guangzhou Medical Ethics Committee of the Chinese Medical Association in Guangzhou, China.
Cognitive measures
Cognitive function was assessed using modified versions of the Delayed Word Recall Test (DWRT) [9] and MMSE. The DWRT involves presenting 10 simple Chinese words (soy sauce, arm, letter, chairman, ticket, grass, corner, stone, book and stick) to participants, who were asked to recall the words. This procedure was repeated three times, then after 5 min, participants were asked to freely recall as many words as possible. Participants who successfully recalled one word were given a score of 1, with a maximum score of 10. The scores from this fourth repetition were analysed as the DWRT score. Cognitive impairment was defined as DWRT score <4, corresponding to 1 standard deviation (SD) below the mean (mean = 5.36; SD = 1.42). It is important to note that references to cognitive impairment do not correspond to a clinical diagnosis of cognitive dysfunction, which requires evaluation by a physician. However, the DWRT and MMSE measures have previously been used in combination as indicators of cognitive impairment [10] [11] [12] .
The original MMSE was modified in 3 of the 11 tasks as follows: item 2 'location' was adapted according to geographical divisions of China and setting, resulting in categories of country, province, city, hospital and floor. For item 3 '3-word recall' the words 'table' and 'penny' were replaced by 'newspaper' and 'train', while the third word 'apple' remained unchanged. This ensured that all words used in the recall task were two-character frequently used Chinese words. Participants could achieve a maximum of 30 points on the 11 MMSE items. A combined total MMSE score was computed and an additional cognitive impairment variable was created, with cognitive impairment defined as MMSE score ≤24 [13] . The MMSE was administered only in the third phase of the GBCS and as such data of the sub-sample of 8,652 participants were analysed.
Glycaemic profile
Blood samples were taken from participants who were asked to fast overnight before arriving at the examination centre in the early morning. Fasting plasma samples were drawn from the venous circulation of the arm and collected in sodium fluoride/potassium oxalate tubes. Samples were stored on ice for a maximum of 3 h before being assessed in the hospital laboratory using a Shimadzu CL-8000 clinical chemical analyser (Shimadzu Corp, Kyoto, Japan). Individuals were categorised using American Diabetes Association clinical definition, giving rise to three fasting blood glucose (FBG) groups: FBG <5.6 mmol/l indicating a normal glycaemic profile, FBG ≥5.6-<7.0 mmol/l indicating an impaired FBG level and FBG ≥7.0 mmol/l indicating the presence of T2DM. Self-reported T2DM was established by asking whether a doctor has previously told participants that they have T2DM.
Additional measures
Education level ( primary or below, secondary, tertiary or above) and self-reported annual personal income were used to indicate socioeconomic status. Self-rated health status was assessed by a subjective four-point rating scale (very good, good, poor or very poor), which was dichotomised into good or poor. Other data from the interviews included selfreported smoking status, alcohol consumption, snoring, physician diagnosed mental illness and use of hypertensive and glucose-lowering medications. Additional clinical measures included waist circumference, BMI, fasting triglyceride, total, LDL-and HDL cholesterol, as well as systolic and diastolic blood pressure.
Statistical analysis
All data analyses were performed in SPSS (version 19.0). T-tests, cross-tabulation and analysis of variance were conducted to compare the cognitively impaired and nonimpaired sub-groups. Logistic regression models were constructed to assess the association between FBG and cognitive impairment (yes/no) as measured by DWRT and MMSE, with the normal glycaemic group as the reference. The odds ratios (ORs) and 95% confidence intervals (CIs) for three hierarchical models are presented: crude; adjusting for age and sex; and additionally adjusting for waist circumference, systolic blood pressure, HDL cholesterol, LDL cholesterol, hypertensive medication, glucose-lowering medication, snoring, educational level, personal income, smoking status, alcohol consumption, self-rated health and mental illness.
Linear regression coefficients were calculated to assess the relationship between FBG and cognitive function as measured by DWRT and MMSE scores (continuous). Analyses were conducted for the whole sample and repeated in sub-groups stratified by impaired FBG level. The logistic and linear regression analyses were computed using the DWRT cognitive measure in the total sample of 27,971 participants and the MMSE measure in a sub-sample of 8,652. Table 1 shows the relationship between cognitive impairment and the demographic and clinical factors. Cognitive impairment was associated with older age, lower education level, lower personal income, smoking, larger waist circumference, worse self-rated health, less snoring, lower levels of HDL-and LDL cholesterol, higher systolic blood pressure and FBG, self-reported T2DM and use of glucose-lowering medication relative to the cognitively non-impaired group.
Results

Demographic and clinical characteristics
Analysis of variance: cognitive function by fasting glucose
There was a significant association between FBG group and cognitive function (P < 0.001) with mean DWRT scores decreasing from 5.6 to 5.4 to 5.3, respectively, across the three groups of increasing FBG (<5.6, ≥5.6-<7.0 and ≥7.0 mmol/L). A similar significant association was observed with mean MMSE scores decreasing from 27.7 to 27.4 to 27.3, respectively, across the three groups (P < 0.001, data not shown).
Logistic regression: fasting glucose and cognitive impairment
The fully adjusted model (model 2) in Table 2 revealed an increased risk of cognitive impairment with increased FBG in the FBG ≥7.0 group, with the adjusted ORs of 1.01 (95% CI 0.93-1.10) and 1.18 (95% CI 1.00-1.40) for FBG ≥5.6-<7.0 and FBG ≥7.0 mmol/l (P for trend = 0.289), respectively, compared with those with FBG <5.6 mmol/l. However, the increased risk of cognitive impairment for MMSE across the FBG groups was no longer significant in the fully adjusted model (Table 2, 
model 2).
Linear regression: fasting glucose and cognitive function Table 3 shows that an increase of 1 mmol/l of FBG was associated with a decrease of 0.02 in DWRT score. The pattern of association differed, with a decrease of 0.02 observed in the FBG ≥7.0 mmol/l group, and an increase of 0.05 observed in the FBG <7.0 mmol/l group, in DWRT score, per mmol/l of FBG. Table 3 shows that an increase of 1 mmol/l of FBG was associated with a decrease of 0.03 in MMSE score; however, the association was not significant in the fully adjusted model. The non-significant association was observed in the FBG <7.0 mmol/l group, with a decrease of 0.08 in MMSE score per mmol/l of glucose, and a decrease of 0.02 in the FBG ≥7.0 mmol/l group.
Discussion
We observed a clear association between increasing FBG level and reduced cognitive function across the glycaemic spectrum, suggesting that dysfunction is associated with increasing glucose levels even in the normoglycaemic range, in the analysis of this large community-based study of older Chinese individuals. Increased risk of cognitive impairment in patients with T2DM has been reported in Western populations [1] [2] [3] with the estimated increased risk ranging between 20 and 60% [14] . However, there is limited evidence of this association in Asian populations. These findings suggest that the characteristic features of diabetes such as hyperglycaemia may play a role in the development of impaired cognition.
Findings of the present study showed that elevated glycaemia was associated with cognitive impairment across the glycaemia spectrum, when cognition was measured with DWRT, suggesting that there are also negative impacts on cognition in those without diabetes. The logistic regression analysis for MMSE demonstrated a greater level of risk of cognitive impairment for the FBG ≥5.6-<7.0 group than the FBG ≥7.0 group; however, these results were not significant in the fully adjusted model. This is also reflected in the MMSE linear regression analyses which also showed a stronger association in the FBG <7.0 group than the FBG ≥7.0 group, which was non-significant in the fully adjusted model. Conversely, the opposite was observed in the DWRT linear regression analyses whereby a positive association was observed in the FBG <7.0 group and FBG was significantly negatively associated with cognition in the FBG ≥7.0 group. The observed association of glycaemia affecting cognition as measured by DWRT in both the diabetes and normoglycaemic range is supported by a large prospective study of over 7,000 Western women with T2DM, impaired fasting glucose (IFG) and normal glucose which indicated that those with IFG had better cognitive function than those with T2DM and worse cognitive function compared with those with normal glucose. Rates of cognitive decline among the IFG group were also intermediate between the T2DM and normal glucose groups [15] , indicating that glycaemia also exerts a negative impact on cognition within samples without diabetes such as those with IFG.
A key strength of the present study is that two different tests of cognition were utilised, the MMSE and DWRT which both showed associations with FBG; however, the associations between the MMSE measure of cognition and FBG were no longer significant in the fully adjusted models. The two tests reflect different aspects of cognition as the MMSE incorporates five neurological aspects: orientation, registration, attention and calculation, recall and language, whilst the DWRT assesses short-term verbal memory only. Interestingly, both tests include verbal memory, which has been shown in a systematic review to be the most commonly affected aspect of cognition among those with T2DM [16] . Our observed association with DWRT suggests that verbal memory in particular is impaired. The observed nonsignificant associations with MMSE provide further support that the other aspects of cognition measured by MMSE are perhaps not as widely affected by glycaemia. The mechanism by which the glycaemic state exerts a negative impact on numerous body systems is likely through a combination of factors including chronic hyperglycaemia, hypoglycaemia, glycation end products, inflammation and cerebral micro-and macro-vascular disease [17] . Vascular and neural pathways are two major potential pathological mechanisms through which FBG may increase the risk of cognitive impairment.
The increased prevalence of micro-and macro-vascular disease resulting from chronic hyperglycaemia in T2DM is an important determinant of the risk of cognitive impairment. T2DM is an established risk factor for stroke and cardiovascular disease [18] which are in turn also associated with higher rates of cognitive impairment [19] . The risk of stroke and major vascular events is increased [Risk Ratio (RR) = 3-6] in patients with T2DM [20, 21] , with these patients more likely to develop ischaemic and clinically silent strokes [22] . Diabetes also impacts on stroke outcome, with T2DM patients experiencing an increased risk (RR = 3.4) in stroke-related dementia [23] . It is thought that glycaemia negatively impacts on cerebrovascular artery circulation through atherosclerosis [24] . Indeed, patients with diabetes have been shown to have higher prevalence of calcified carotid atheroma compared with those without diabetes [25] , which illustrates the negative impact of glycaemia in the development of atherosclerosis and associated cerebrovascular complications.
Neural pathways are also negatively affected by glycaemia via the accumulation of advanced glycation end products (AGEs), which may increase cognitive impairment. AGEs form through a series of reactions between glucose and macromolecules, and in hyperglycaemia AGE formation is accelerated [26] . Increased AGE levels have been shown in individuals with dementia [27] and higher levels have been associated with greater decline in cognitive function in individuals without dementia [28] . A deeper understanding of the role of glycaemia in the development of cognitive impairment may enable the identification of potential pathways that can be targeted to modify an individuals' risk by careful management of hyperglycaemia.
Further studies investigating cognitive impairment and glycaemia must employ rigorous methodology, as previous studies have been criticised for having small sample sizes, not accounting for individual differences in education and not adjusting for confounders [29] . The present study has addressed all of those methodological issues and is to our knowledge the largest study to examine cognition across the glucose spectrum. However, the present study has some limitations. The cross-sectional design means that it is not possible to confirm a causal relationship between diabetes and cognition. The sample selected for the present study is unlikely to be representative of the general population of Guangzhou, as there is 'potential healthy volunteer bias' with those with severe cognitive impairment being less likely to participate. However, those individuals included in the study were an unselected sample of the GHHARE, who have been shown to have similar prevalence rates of diabetes to a nationally representative sample of urban Chinese [30] , which supports the extrapolation of the results.
In conclusion, this is the largest study to investigate the impact of glycaemia on cognition in both individuals with and without diabetes. The results demonstrate that increasing glycaemia across the spectrum, and specifically in the diabetes range was significantly associated with increased risk for cognitive impairment when cognition was measured by DWRT. Our findings are of clinical importance as individuals with type 2 diabetes and cognitive impairment may be less capable of engaging in self-management practices and thus may require more help with self-care. There is also potential that awareness of increased cognitive risk could enhance motivation for individuals with type 2 diabetes to maintain strict glycaemic control, thus preventing these individuals from developing cognitive impairment.
Key points
• This is the largest study to examine cognitive function across the glucose spectrum including those with and without diabetes.
• Our findings demonstrate that increasing glycaemia across the spectrum was associated with increased cognitive impairment.
• This study adds to the existing knowledge base examining the impact of glycaemia on cognition in a less studied non-Caucasian population.
• Our findings are of clinical importance as individuals with type 2 diabetes and cognitive impairment may require additional support in engaging with self-care and selfmanagement.
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